Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human GLB1 Anticorps:
anti-Mouse (Murine) GLB1 Anticorps:
anti-Rat (Rattus) GLB1 Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Escherichia coli (E. coli) Monoclonal GLB1 Primary Antibody pour ICC, WB - ABIN93909
Dráber, Slavícková, Sládecek, Viklický: Monoclonal antibodies to Escherichia coli beta-galactosidase and their use for detection and purification of recombinant expression products. dans Hybridoma 1992
Show all 2 Pubmed References
Bacteria Polyclonal GLB1 Primary Antibody pour IHC (fro), IHC (p) - ABIN2477639
Meyers, Zepeda, Murdock: Alcohol and trauma. An endemic syndrome. dans The Western journal of medicine 1990
Show all 2 Pubmed References
Escherichia coli (E. coli) Polyclonal GLB1 Primary Antibody pour IF, IP - ABIN1607729
Biju, Marks, Mast, Fadool: Deletion of voltage-gated channel affects glomerular refinement and odorant receptor expression in the mouse olfactory system. dans The Journal of comparative neurology 2007
Escherichia coli (E. coli) Polyclonal GLB1 Primary Antibody pour DB, IP - ABIN99522
Shearer, Fragoso, Clagett-Dame, McCaffery: Astrocytes as a regulated source of retinoic acid for the brain. dans Glia 2012
Bacteria Monoclonal GLB1 Primary Antibody pour ELISA, ICC - ABIN251060
Durbin, Bodmer: A sensitive micro-immunoassay using beta-galactosidase/anti-beta-galactosidase complexes. dans Journal of immunological methods 1987
Bacteria Monoclonal GLB1 Primary Antibody pour IA - ABIN259574
Chung, Kim, Andrew: Uncoupling apical constriction from tissue invagination. dans eLife 2017
We confirmed a diagnosis of GM1 gangliosidosis based on GLB1 mutations and/or the deficiency of beta-galactosidase activity. We identified the first two cases by whole-exome sequencing, and then the other six cases by direct sequencing of GLB1 with enzyme analysis. The recurrent mutation, p.D448V in GLB1, accounted for 50.0% of total alleles in our cohort.
we showed for the first time the specific alteration of beta-Galctosidase (Gal), beta-Galactosylcerebrosidase (GALC) in MCI patients. It is notable that in above peripheral biological samples the lysosomes are more sensitive to AD cellular metabolic alteration when compared to levels of Abeta-peptide or Tau proteins, similar in both AD groups analyzed
GLB1 rs4678680 SNP contributes to susceptibility to develop HBV-related hepatocellular carcinoma
beta-Gal expression in articular cartilage is associated with progressive knee osteoarthritis joint damage and is a potential indictor of disease severity.
This study shows that moderate widespread expression of betagal in the CNS of GM1 gangliosidosis mice is sufficient to achieve significant biochemical impact with phenotypic amelioration and extension in lifespan
The study proposes an explanation for ELNR1 uncoupling based on the age-related alterations of Neu-1 activity.
Overexpression of the novel senescence marker GLB1 in prostate cancer predicts reduced recurrence of PSA-expressing tumors.
Identification and analysis of GLB1 mutations in Indian patients with GM1 gangliosidosis.
We observed significant lower values of beta-galactosidase, FUC and tendency to decrease of MAN and GLU concentration in nasal polyps
This study analyzed patient cells with GM1 gangliosidosis and sialidosis. A novel mutation p.E186A is identified in GLB1 gene.
The activity of serum GAL was significantly higher in colon cancer patients with a history of alcohol and nicotine dependence.
beta-galactosidase, considered as a senescence marker, is over-expressed only in specific subtypes of pituitary adenomas, but is also present in carcinomas considered as a group
In the serum of patients with Lyme disease, GAL activity significantly increased (p = 0.029), and the activity of FUC had a tendency to increase (p = 0.153), compared to the control group.
In a Turkish population, mutations in GLB1 gene leads to severely deficient enzyme activity and result in infantile phenotype of the GM1 gangliosidosis.
GLB alleles have a role in GM1-gangliosidosis and Morquio B disease, and fluorous iminoalditols act as effective pharmacological chaperones against their gene products
Elastin derived peptides may play a role in neovascular age-related macular degeneration by binding to and inducing neovascular phenotypes in choroidal endothelial cells through their receptor, GLB1.
The non-random distribution of plasma membrane-associated beta-hexosaminidase and beta-galactosidase and their localization within lipid microdomains, suggest a role of these enzymes in the local reorganization of glycosphingolipid-based signalling units.
We show here that mouse GLB1 has greater stability when compared to human GLB1, and that human GLB1 activity is temperature and protective-dependent on protein cathepsin A, while that of mouse GLB1 is not
Crystal structure of human beta-galactosidase: structural basis of Gm1 gangliosidosis and morquio B diseases.
Plasma beta-galactosidase and beta-hexosaminidase levels are higher in patients with Alzheimer's disease-type 2 diabetes mellitus (T2DM) compared to those with T2DM alone.
Functional loss of glucocerebrosidase or beta-Gal promotes toxic conversion of alphaSyn via aberrant interactions between alphaSyn and their substrate glycolipids, leading to aggravation of alphaSyn-mediated neurodegeneration.
A significant proportion of p16Ink4a/senescence-associated beta-galactosidase-positive cells accumulating in aging mice are macrophages that acquired this phenotype as part of their physiological reprogramming towards an M2-like phenotype.
Senescence-associated-beta-gal activity in neurons cannot be attributed uniquely to cell senescence either in vitro or in vivo.
beta-gal is present in the pro-urine from where it is thought to stimulate TRPV5 activity.
Senescence-associated beta-galactosidase is present in apical vacuoles of visceral endoderm in developing mouse embryos.
This protein was used as a biological marker of cell lineage, cell differentiation, and cell movement in the mouse cerebellum.
This gene encodes beta-galactosidase-1, a lysosomal enzyme that hydrolyzes the terminal beta-galactose from ganglioside substrates and other glycoconjugates. Defects in this gene are the cause of GM1-gangliosidosis and Morquio B syndrome. Multiple transcript variants encoding different isoforms have been found for this gene.
, elastin receptor 1, 67kDa
, beta-galactosidase complex
, beta-galactosidase electrophoretic
, beta-galactosidase systemic regulator
, beta-galactosidase temporal
, lysosomal beta-galactosidase